1 Definition
Chemotherapies can be classified according to their emetogenic potential in: highly emetogenic chemotherapies (almost all patients not receiving antiemetic prophylaxis suffer from CINV; i.e., cisplatin, dacarbazine); moderately emetogenic chemotherapies (many, but not all, patients suffer from CINV if not treated; i.e., cyclophosphamide- and anthracycline-containing chemotherapies); chemotherapies with a low emetogenic potential (only a very few patients who do not receive antiemetic prophylaxis experience CINV).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsEditor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media LLC
About this entry
Cite this entry
(2010). Emetogenicity of Chemotherapies. In: Preedy, V.R., Watson, R.R. (eds) Handbook of Disease Burdens and Quality of Life Measures. Springer, New York, NY. https://doi.org/10.1007/978-0-387-78665-0_5578
Download citation
DOI: https://doi.org/10.1007/978-0-387-78665-0_5578
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-78664-3
Online ISBN: 978-0-387-78665-0
eBook Packages: MedicineReference Module Medicine